Home Tags EpiPen
Welcome to Dispensed, Business Insider's weekly newsletter giving you a dose of pharma, biotech, and healthcare news.
People rely on the EpiPen in life-or-death situations, but the devices are remarkably hard to test. Here’s why.
Testing lifesaving EpiPens before they get to patients is challenging because testing destroys them, according to the EpiPen's manufacturer.
EpiPens weren’t working. It took 3 years and the FDA stepping in before serious change — with potentially deadly outcomes
Consumer complaints about EpiPens were increasing, but its manufacturer wasn’t properly looking into those complaints, FDA inspectors warned in 2014.
Drug giant Novartis is gearing up to release a cheaper EpiPen rival, but one big factor may make competition tricky
The Thursday announcement shows an end in sight for the 17-month saga that has stretched since Symjepi was first approved by U.S. regulators.
The strange history of the EpiPen, the device developed by the military that turned into a billion-dollar business and now faces generic competition b...
Here's the story of how a common, lifesaving device became a controversial drug-pricing story, facing recalls, shortages, and now generic competition between Mylan and Teva.
Mylan stock dropped over 7% after it released its second quarter earning report. The company then announced that it was to undergo a strategic review.
The FDA on Wednesdsay said that there's a shortage of EpiPens in the US. Mylan, the company that distributes the emergency allergy medication, said that there are "intermittent supply constraints," but supply is available.
Mylan’s shareholders just voted against its executive pay, which included a $100 million package for its chairman
Mylan shareholders voted to re-elect the generic drugmaker's board at its annual meeting on Thursday, despite a push to to vote down most of the directors.
Shareholder advocacy groups are telling Mylan investors to show no mercy with the board at an upcoming shareholder meeting.
Executives at Mylan, the maker of EpiPen, are richly compensated — shareholders think maybe too richly.